$104.64
5.43% yesterday
Nasdaq, May 02, 10:00 pm CET
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Blueprint Medicines Corp. Stock price

$104.64
+14.63 16.25% 1M
+12.76 13.89% 6M
+17.42 19.97% YTD
-2.36 2.21% 1Y
+44.92 75.22% 3Y
+46.51 80.01% 5Y
+83.83 402.84% 10Y
Nasdaq, Closing price Fri, May 02 2025
+5.39 5.43%
ISIN
US09627Y1091
Symbol
BPMC
Sector
Industry

Key metrics

Market capitalization $6.76b
Enterprise Value $6.87b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.49
P/S ratio (TTM) P/S ratio 13.28
P/B ratio (TTM) P/B ratio 22.32
Revenue growth (TTM) Revenue growth 104.04%
Revenue (TTM) Revenue $508.82m
EBIT (operating result TTM) EBIT $-212.05m
Free Cash Flow (TTM) Free Cash Flow $-197.22m
Cash position $615.49m
EPS (TTM) EPS $-1.07
P/E forward negative
P/S forward 9.37
EV/Sales forward 9.52
Short interest 9.80%
Show more

Is Blueprint Medicines Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,786 stocks worldwide.

Blueprint Medicines Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Blueprint Medicines Corp. forecast:

17x Buy
74%
5x Hold
22%
1x Sell
4%

Analyst Opinions

23 Analysts have issued a Blueprint Medicines Corp. forecast:

Buy
74%
Hold
22%
Sell
4%

Financial data from Blueprint Medicines Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
509 509
104% 104%
100%
- Direct Costs 36 36
17% 17%
7%
472 472
117% 117%
93%
- Selling and Administrative Expenses 343 343
28% 28%
67%
- Research and Development Expense 325 325
22% 22%
64%
-196 -196
58% 58%
-38%
- Depreciation and Amortization 16 16
12% 12%
3%
EBIT (Operating Income) EBIT -212 -212
56% 56%
-42%
Net Profit -67 -67
87% 87%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about Blueprint Medicines Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Blueprint Medicines Corp. Stock News

Neutral
Seeking Alpha
2 days ago
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business Communications Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Becker Hewes - Chief Medical Officer Mike Landsittel - Chief Financial Officer Christy Rossi - Chief Operating O...
Neutral
PRNewsWire
2 days ago
-- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -- --  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria – CAMBRIDGE, Mass. , May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC...
Neutral
PRNewsWire
8 days ago
CAMBRIDGE, Mass. , April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
More Blueprint Medicines Corp. News

Company Profile

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Head office United States
CEO Kathryn Haviland
Employees 649
Founded 2008
Website www.blueprintmedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today